Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call
13 Mai 2023 - 2:15AM
Business Wire
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the
leader in enabling the development and supply of better treatments
for patients worldwide, today announced that in light of the
circumstances described in the Company’s Form 12b-25 filed on May
11, 2023, with the Securities and Exchange Commission, and the
Company’s ongoing focus on finalizing its financial statements and
other disclosures in its Quarterly Report on Form 10-Q for the
fiscal quarter ended March 31, 2023 (the “Form 10-Q”) and
completing its quarterly closing processes and procedures, it will
be postponing the release of its financial results for the third
quarter of fiscal year 2023, ended March 31, 2023, and the
conference call previously scheduled for Monday, May 15, 2023 at
8:15 a.m. ET, until Friday, May 19, 2023 at 8:15 a.m. ET.
Third Quarter Fiscal Year 2023 Earnings Conference
Webcast
The Company now expects to release financial results for the
third quarter of fiscal year 2023, ended March 31, 2023, before the
market open on Friday, May 19, 2023, and will host a webcast to
discuss the results at 8:15 a.m. ET on the same day. Catalent
invites all interested parties to listen to the webcast and view a
supplemental slide presentation, both of which will be accessible
through Catalent’s website at https://investor.catalent.com. The
webcast replay, along with the supplemental slides, will be
available for 90 days at https://investor.catalent.com.
About Catalent
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
global leader in enabling pharma, biotech, and consumer health
partners to optimize product development, launch, and full
life-cycle supply for patients around the world. With broad and
deep scale and expertise in development sciences, delivery
technologies, and multi-modality manufacturing, Catalent is a
preferred industry partner for personalized medicines, consumer
health brand extensions, and blockbuster drugs. Catalent helps
accelerate over 1,000 partner programs and launch over 150 new
products every year. Its flexible manufacturing platforms at over
50 global sites supply around 80 billion doses of nearly 8,000
products annually. Catalent’s expert workforce of approximately
18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly
$5 billion in revenue in its 2022 fiscal year. For more information
www.catalent.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding management’s ongoing review of its third fiscal quarter
financial statements and the release of the Company’s fiscal third
quarter results. These forward-looking statements are based on
management’s current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause actual
future events, results or achievements to be materially different
from the Company’s expectations and projections expressed or
implied by the forward-looking statements. The important factors
include, but are not limited to, the finalization of the Company’s
third quarter financial statements, completion of the Company’s
quarterly closing processes and procedures, as well as the general
business, financial and accounting risks and the other important
factors discussed under the caption “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended June 30, 2022, filed
with the U.S. Securities and Exchange Commission, or the SEC, and
the Company’s other filings with the SEC. Forward-looking
statements speak only as of the date of this press release and are
based on information available to the Company as of the date of
this press release, and the Company assumes no obligation to update
such forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230512005371/en/
Investor Contact: Paul Surdez, Catalent, Inc. (732) 537-6325
investors@catalent.com
Media Contact: Chris Halling +44 (0)7580 041073
media@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024